EGFR and non-small cell lung carcinoma: Although PD‐L1 expression and driver mutations (e.g., EGFR, ALK) are established predictive biomarkers for ICIs in advanced NSCLC, these factors were not systematically analyzed in the present study due to data incompleteness.